Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM529D1
- Development stage
- Preclinical
- Lead developer
- Keymed Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CM529D1 is a bispecific antibody-drug conjugate (ADC) developed by Keymed Biosciences for the treatment of small cell lung cancer (SCLC). The therapeutic is designed to simultaneously target two antigens frequently expressed in neuroendocrine tumors: Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6). By utilizing a bispecific antibody architecture, CM529D1 aims to enhance tumor specificity and payload delivery compared to monospecific agents. Keymed Biosciences has submitted an Investigational New Drug (IND) application for the candidate, positioning it in the early stages of clinical development.
- Other names
- CM529D1CM-529D1CM 529D1
02
Targets
SEZ6DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on CM529D1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM529D1.